Welcome to our dedicated page for Translational Dev Acquisition SEC filings (Ticker: TDACU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Translational Dev Acquisition's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Translational Dev Acquisition's regulatory disclosures and financial reporting.
Translational Development Acquisition Corp. reported net income of $1,332,797 for the quarter ended March 31, 2026, driven by $1,613,958 of dividends on trust investments and offset by $281,161 of general and administrative costs. Cash outside the trust was very limited at $24,630, with marketable securities in the trust account totaling $183,271,269.
As of March 31, 2026, the company had a working capital deficit of $785,769 and relies on a non‑interest‑bearing promissory note from its sponsor of up to $2,000,000, of which $500,000 was outstanding. Management discloses substantial doubt about the company’s ability to continue as a going concern because it must complete a business combination by June 24, 2026 or liquidate.
The structure remains typical for a SPAC, with 17,250,000 Class A ordinary shares classified as redeemable at approximately $10.62 per share and 4,657,500 Class B founder shares outstanding. Management also concluded that disclosure controls and procedures were not effective due to an omission of the internal control report in the prior annual filing.
Translational Development Acquisition Corp. reported net income of $1,332,797 for the quarter ended March 31, 2026, driven by $1,613,958 of dividends on trust investments and offset by $281,161 of general and administrative costs. Cash outside the trust was very limited at $24,630, with marketable securities in the trust account totaling $183,271,269.
As of March 31, 2026, the company had a working capital deficit of $785,769 and relies on a non‑interest‑bearing promissory note from its sponsor of up to $2,000,000, of which $500,000 was outstanding. Management discloses substantial doubt about the company’s ability to continue as a going concern because it must complete a business combination by June 24, 2026 or liquidate.
The structure remains typical for a SPAC, with 17,250,000 Class A ordinary shares classified as redeemable at approximately $10.62 per share and 4,657,500 Class B founder shares outstanding. Management also concluded that disclosure controls and procedures were not effective due to an omission of the internal control report in the prior annual filing.
Translational Development Acquisition Corp. disclosure: The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly report shared voting and dispositive power over 1,054,120 Class A ordinary shares (CUSIP G9008W105), representing 6.1% of the class as shown on the cover page. The filing includes a Joint Filing Agreement and exhibits clarifying that the holdings are reported by Goldman Sachs reporting units and that Goldman Sachs & Co. LLC is a subsidiary of GS Group. The signature block shows the filing was executed on 05/07/2026.
Translational Development Acquisition Corp. disclosure: The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly report shared voting and dispositive power over 1,054,120 Class A ordinary shares (CUSIP G9008W105), representing 6.1% of the class as shown on the cover page. The filing includes a Joint Filing Agreement and exhibits clarifying that the holdings are reported by Goldman Sachs reporting units and that Goldman Sachs & Co. LLC is a subsidiary of GS Group. The signature block shows the filing was executed on 05/07/2026.
Translational Development Acquisition Corp. filed Amendment No. 2 to its 2025 annual report to revise its conclusion on disclosure controls and procedures. Management, including the chief financial officer, now concludes that as of December 31, 2025 these disclosure controls and procedures were not effective.
The company states that internal control over financial reporting, assessed using the COSO 2013 framework, was effective as of December 31, 2025, and notes no material changes in these controls during the most recent fiscal quarter. The amendment also adds updated Section 302 and Section 906 Sarbanes-Oxley officer certifications, with no other changes to the original Form 10-K or prior amendment.
Translational Development Acquisition Corp. filed Amendment No. 2 to its 2025 annual report to revise its conclusion on disclosure controls and procedures. Management, including the chief financial officer, now concludes that as of December 31, 2025 these disclosure controls and procedures were not effective.
The company states that internal control over financial reporting, assessed using the COSO 2013 framework, was effective as of December 31, 2025, and notes no material changes in these controls during the most recent fiscal quarter. The amendment also adds updated Section 302 and Section 906 Sarbanes-Oxley officer certifications, with no other changes to the original Form 10-K or prior amendment.
Translational Development Acquisition Corp. filed Amendment No. 1 to its 2025 annual report to update its controls and procedures disclosure. The company is responding to an SEC comment letter by replacing Item 9A and providing new officer certifications, while leaving all other 10-K disclosures unchanged.
Management, including the chief financial officer, evaluated disclosure controls and procedures as of December 31, 2025 and concluded they were effective. Using the COSO 2013 framework, management also determined internal control over financial reporting was effective, with no material changes during the most recent fiscal quarter.
The filing notes aggregate market value of Class A ordinary shares of $177,675,000 as of June 30, 2025. As of March 30, 2026, 17,250,000 Class A ordinary shares and 4,657,500 Class B ordinary shares were issued and outstanding.
Translational Development Acquisition Corp. filed Amendment No. 1 to its 2025 annual report to update its controls and procedures disclosure. The company is responding to an SEC comment letter by replacing Item 9A and providing new officer certifications, while leaving all other 10-K disclosures unchanged.
Management, including the chief financial officer, evaluated disclosure controls and procedures as of December 31, 2025 and concluded they were effective. Using the COSO 2013 framework, management also determined internal control over financial reporting was effective, with no material changes during the most recent fiscal quarter.
The filing notes aggregate market value of Class A ordinary shares of $177,675,000 as of June 30, 2025. As of March 30, 2026, 17,250,000 Class A ordinary shares and 4,657,500 Class B ordinary shares were issued and outstanding.
Translational Development Acquisition Corp. reports its 2025 results as a blank check company focused on completing an initial business combination. It completed an IPO of 17,250,000 units at $10.00 each, plus 7,075,000 private placement warrants at $1.00, placing $174,225,000 into a trust at $10.10 per public share.
At December 31, 2025, investments in the trust totaled $181,657,311 and the company recorded net income of $6,362,427, driven by $7,306,965 of dividends on trust investments and $944,538 of operating costs. Cash outside the trust was $29,787 with a working capital deficit of $504,608.
The company has until June 24, 2026 to complete a business combination or redeem public shares and liquidate. Management discloses substantial doubt about its ability to continue as a going concern absent a timely deal or further sponsor support, while highlighting shareholder redemption protections and the sponsor’s limited indemnity for certain creditor claims.
Translational Development Acquisition Corp. reports its 2025 results as a blank check company focused on completing an initial business combination. It completed an IPO of 17,250,000 units at $10.00 each, plus 7,075,000 private placement warrants at $1.00, placing $174,225,000 into a trust at $10.10 per public share.
At December 31, 2025, investments in the trust totaled $181,657,311 and the company recorded net income of $6,362,427, driven by $7,306,965 of dividends on trust investments and $944,538 of operating costs. Cash outside the trust was $29,787 with a working capital deficit of $504,608.
The company has until June 24, 2026 to complete a business combination or redeem public shares and liquidate. Management discloses substantial doubt about its ability to continue as a going concern absent a timely deal or further sponsor support, while highlighting shareholder redemption protections and the sponsor’s limited indemnity for certain creditor claims.